Stefanie Zschäbitz, Head of Translational Uro-Oncology at Heidelberg University Hospital, shared Medtoday Germany’s post on LinkedIn, adding:
“We can look forward to several positive Phase 3 studies in the field of oncology at the American Society of Clinical Oncology (ASCO) GU in San Francisco. Great news for our patients!
Among other things, we will see data from the Litespark 11 study, in which we participate. Thanks to Maximilian Jenzer, Ulrike Lauterbach, Stephanie Cordeiro de Lima, Alexandra Ivanova, Lena Wucherpfennig, Daniel Seebach-Schielzeth, Ramona Stelmach, Oliver Sedlaczek, Verena Turco and the many other colleagues from our study team who are involved in the care of the study participants on a daily basis. Thank you to our patients who decide to enrol in the study!”
Quoting Medtoday Germany’s post:
“ASCO Direct GU 2026 – Save the Date
Join us on March 1st and secure 5 CME points when medtoday starts reporting from San Francisco on the ASCO Genitourinary Cancers Symposium.
Our experts will report on the most exciting study results in urology and uro-oncology for you directly from ASCO GU. On medtoday.de you will find state-of-the-art contributions (from 16 February) and highlight contributions (LIVE and on demand from 1 March) curated and discussed by our top-class experts.
Main topics:
Bladder carcinoma (PD Dr. Stefanie Zschäbitz )
Testicular and penile cancer (Prof. David Pfister)
Localized Prostate Cancer and Diagnostics (Prof. Jürgen Gschwend)
Metastatic prostate cancer (Prof. Gunhild von Amsberg )
Renal Cell Carcinoma (Prof. Viktor Grünwald )
Personal, compact and in slide-based video contributions, we bring all relevant information to your home!
With the kind support of Johnson and Johnson, MSD Sharp and Dohme Gesellschaft mit beschrankter Haftung”
Other articles on OncoDaily.
